CMB&RM seminar: Exploitation of the LRG1-regulated TGF? signaling in cardiovascular diseases: a doubled-edged sword?
|Starts:||13:00 5 Oct 2018|
|Ends:||14:00 5 Oct 2018|
|What is it:||Seminar|
|Organiser:||Faculty of Biology, Medicine and Health|
|Who is it for:||University staff, Current University students|
Xiaomeng is interested in the role of TGF? signalling in development and under disease conditions. Her earlier work demonstrated that type IV collagen not only function as an affinity matrix for binding and immobilizing TGF? family growth factor, Decapentaplegic (Dpp), but also regulates its signalling during Drosophila development. Her recent study led to the identification of another novel regulator of TGF? signalling, Leucine rich alpha 2 glycoprotin 1 (Lrg1). This work revealed for the first time the function and molecular mechanism of Lrg1 regulated TGF? signalling in pathological angiogenesis and raised the intriguing possibility of targeting Lrg1 as a novel treatment for diseases such as diabetic vascular complications, cancer, atherosclerosis and rheumatoid arthritis. Both studies have been published in Nature as an article.?
Role: Assistant Professor
Organisation: Nanyang Technological University (NTU Singapore)
Travel and Contact Information
Michael Smith Building